In Depth 23 Apr 2025 The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval …side effects. Preliminary study results for the multiple sclerosis trials are expected in April 2026. Biogen pushes on with in-house BTK inhibitor despite dropping licensed BTK asset belonging to InnoCare… April 23, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2025 BIO-Europe partnering: Australian biotech companies share their experiences …get a bigger variety of companies from Asia and Europe, as well as the Americans.” BIO-Europe partnering is attractive to Aussie biotechs Pursey was not alone among Australian biotechs in… November 10, 2025 - 9 minutesmins - By Dylan Kissane Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2022 New Labiotech Health Awareness Days listings page Earlier this year, we added a page to the website with all of the global events and conferences taking place. It’s been very well received, and we’ve had plenty of… November 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 18 Jun 2025 From undruggable to oral therapy: The rise of STAT6 degraders …but degradable, showing efficacy in humans. As the clinical data for KT‑621 and other candidates mature through 2025 and 2026, the biotech and medical communities will surely be watching closely…. June 18, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 May 2025 Seven lung cancer companies advancing new treatments in 2025 …like Keytruda, and other targeted therapies already exist to treat both NSCLC and SCLC, biotech companies continue to work on developing more effective treatments for lung cancer. In this article,… May 20, 2025 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Inside Labiotech 12 Feb 2019 Why We Love Being the Main Media Partner of BIO-Europe …are the biggest and best biotech conferences in Europe. More than 2,500 participants attend each event and participate inmore than 14,500 partnering meetings. This is where this conference excels: its… February 12, 2019 - 2 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2022 XtalPi and CK Life Sciences partner on tumor vaccine R&D …of 11.53% from 2022 to 2026. The expected market size by 2026 will be approximately $12 billion. Tumor vaccines targeting different tumor neoantigens, tumor-associated antigens (TAA) and tumor-specific antigens (TSA)… November 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 7 Oct 2025 AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain …pain. The biotech plans to move into phase 3 trials in 2026, positioning itself in a therapeutic area where need is high and progress has been scarce. Table of contents… October 7, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 28 May 2025 New weight loss drugs: Biotech’s mission to end obesity …of disease, with a flurry of biotech companies racing to develop new weight loss drugs that are more and more effective in reducing obesity, as well as producing fewer side… May 28, 2025 - 17 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 3 Dec 2025 Boehringer Ingelheim’s pipeline activity: A busy year of dealmaking for the German pharma in 2025 …2026. In 2022 and 2023, Boehringer Ingelheim made two more eye disease deals – with Surrozen to research and develop SZN-413 for the treatment of retinal diseases, and with RetinAI to make use of RetinAI’s discovery… December 3, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 1 Dec 2025 Stem cell therapy’s avant-garde: Eight companies leading the way …for this setting. Sana Biotechnology Founded: 2018 Headquarters: Seattle, Washington, U.S. Lead program: UP421 Sana Biotechnology develops engineered pluripotent stem cells and donor-derived cells designed to function as off-the-shelf medicines. Its… December 1, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2025 First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? …the outpouring protest from Congress, the patient community, and biopharma industry, the 2026 date was preponed to September, and ultimately resulted in a win for patients and the biotech last… September 29, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email